Stromal interleukin-33 promotes regulatory T cell-mediated immunosuppression in head and neck squamous cell carcinoma and correlates with poor prognosis-Reference-Cited by-同舟云学术

Stromal interleukin-33 promotes regulatory T cell-mediated immunosuppression in head and neck squamous cell carcinoma and correlates with poor prognosis

Published:2018-10-25 Issue:2 Volume:68 Page:221-232
ISSN:0340-7004
Container-title:Cancer Immunology, Immunotherapy
language:en
Short-container-title:Cancer Immunol Immunother

Author:

Wen Yi-hui,Lin Han-qing,Li Hang,Zhao Yi,Lui Vivian Wai Yan,Chen Lin,Wu Xing-mei,Sun Wei,Wen Wei-ping

Funder

Natural Science Foundation of Guangdong Province

Sun Yat-Sen University 5010 Plan

Guangzhou Science and Technology Program key projects

General Research Fund from the Research Grant Council, Hong Kong

Theme-based Research from the Research Grant Council, Hong Kong

Direct Grant for Research, the Chinese University of Hong Kong

National Natural Science Foundation of China

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology,Immunology,Immunology and Allergy

Link

http://link.springer.com/article/10.1007/s00262-018-2265-2/fulltext.html

Reference35 articles.

1. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A (2015) Global cancer statistics, 2012. CA Cancer J Clin 65:87–108

2. Ferris RL, Blumenschein G Jr, Fayette J, Guigay J, Colevas AD, Licitra L, Harrington K, Kasper S, Vokes EE, Even C, Worden F, Saba NF, Iglesias Docampo LC, Haddad R, Rordorf T, Kiyota N, Tahara M, Monga M, Lynch M, Geese WJ, Kopit J, Shaw JW, Gillison ML (2016) Nivolumab for recurrent squamous-cell carcinoma of the head and neck. N Engl J Med 375:1856–1867

3. Harrington KJ, Ferris RL, Blumenschein G Jr, Fayette CAD, Licitra J, Kasper L, Even S, Vokes C, Worden EE, Saba F, Kiyota NF, Haddad N, Tahara R, Grunwald M, Shaw V, Monga JW, Lynch M, Taylor M, DeRosa F, Morrissey M, Cocks L, Gillison K, Guigay ML J (2017) Nivolumab versus standard, single-agent therapy of investigator’s choice in recurrent or metastatic squamous cell carcinoma of the head and neck (CheckMate 141): health-related quality-of-life results from a randomised, phase 3 trial. Lancet Oncol 18:1104–1115

4. Li Q, Prince ME, Moyer JS (2015) Immunotherapy for head and neck squamous cell carcinoma. Oral Oncol 51:299–304

5. Ferris RL (2015) Immunology and immunotherapy of head and neck cancer. J Clin Oncol 33::3293–3304

Cited by 43 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Targeting IL-33 reprograms the tumor microenvironment and potentiates antitumor response to anti-PD-L1 immunotherapy;Journal for ImmunoTherapy of Cancer;2024-09

2. ST2L promotes VEGFA-mediated angiogenesis in gastric cancer by activating TRAF6/PI3K/Akt/NF-κB pathway via IL-33;2024-07-04

3. Current Landscape of Cancer Immunotherapy: Harnessing the Immune Arsenal to Overcome Immune Evasion;Biology;2024-04-28

4. Deciphering the developmental trajectory of tissue-resident Foxp3+ regulatory T cells;Frontiers in Immunology;2024-03-28

5. The effect of interleukin-33 expression on prognosis in patients with nasopharyngeal carcinoma;Acta Otorrinolaringologica (English Edition);2024-02